 The vast majority of chronic myeloid leukemia patients express a BCR-ABL1 fusion gene mRNA encoding a 210 kDa tyrosine kinase which promotes leukemic transformation.     ///    "A possible differential impact of the corresponding BCR-ABL1 transcript variants e13a2 (""b2a2"") and e14a2 (""b3a2"") on disease phenotype and outcome is still a subject of debate. "    ///    "However, clinical outcome under imatinib treatment was comparable and no risk prediction can be made according to e13a2 versus e14a2 BCR-ABL1 transcript type at diagnosis. "    ///    Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.. 